Northern Trust Corp Acquires 80,090 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Northern Trust Corp boosted its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 9.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 892,425 shares of the life sciences company's stock after purchasing an additional 80,090 shares during the period. Northern Trust Corp owned about 1.16% of Integra LifeSciences worth $20,240,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in IART. Arrowstreet Capital Limited Partnership boosted its stake in Integra LifeSciences by 7.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock valued at $312,000 after buying an additional 913 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in shares of Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 1,371 shares in the last quarter. Sterling Capital Management LLC grew its holdings in shares of Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after purchasing an additional 1,931 shares during the last quarter. Covestor Ltd increased its position in shares of Integra LifeSciences by 61.8% during the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock worth $123,000 after purchasing an additional 2,071 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its position in Integra LifeSciences by 5.3% in the fourth quarter. MetLife Investment Management LLC now owns 41,749 shares of the life sciences company's stock valued at $947,000 after buying an additional 2,111 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Trading Down 1.2%

Shares of Integra LifeSciences stock opened at $13.51 on Wednesday. Integra LifeSciences Holdings Co. has a 52-week low of $11.60 and a 52-week high of $32.66. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The firm has a 50-day moving average of $18.59 and a 200-day moving average of $21.81. The stock has a market cap of $1.05 billion, a PE ratio of -150.09, a PEG ratio of 0.73 and a beta of 1.27.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.02). The company had revenue of $382.65 million for the quarter, compared to analyst estimates of $381.17 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business's revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period last year, the company posted $0.55 earnings per share. As a group, sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on IART. JPMorgan Chase & Co. decreased their price target on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Truist Financial dropped their price objective on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a report on Friday, April 11th. Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. JMP Securities reduced their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. Finally, Wells Fargo & Company decreased their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Four investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $18.63.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.